AGGREGATION OF PROTEINS: THERAPEUTIC STRATEGIES, DIAGNOSIS AND APPLICATIONS (Q3145492): Difference between revisions
Jump to navigation
Jump to search
(Created claim: summary (P836): AMYLOID PROTEIN AGGREGATION IS ASSOCIATED WITH AN INCREASING NUMBER OF DEBILITATING OR EVEN FATAL DISORDERS. THERE IS AN URGENT NEED FOR DIAGNOSIS AND TREATMENT OF THESE DISEASES, NOT ONLY TO PREVENT THE SUFFERING OF PATIENTS, BUT ALSO TO REDUCE THE ECONOMIC AND EMOTIONAL BURDEN THAT FALLS ON THE REST OF THE POPULATION. THIS PROJECT AIMS TO TAKE ADVANTAGE OF OUR EXPERIENCE IN THE AREA TO MOVE FORWARD IN THIS DIRECTION, CONCENTRATING ON TWO DISEA...) |
(Changed label, description and/or aliases in en: translated_label) |
||
| label / en | label / en | ||
AGGREGATION OF PROTEINS: THERAPEUTIC STRATEGIES, DIAGNOSIS AND APPLICATIONS | |||
Revision as of 13:48, 12 October 2021
Project Q3145492 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | AGGREGATION OF PROTEINS: THERAPEUTIC STRATEGIES, DIAGNOSIS AND APPLICATIONS |
Project Q3145492 in Spain |
Statements
154,275.0 Euro
0 references
308,550.0 Euro
0 references
50.0 percent
0 references
30 December 2016
0 references
31 December 2020
0 references
UNIVERSIDAD AUTONOMA DE BARCELONA
0 references
42°13'24.28"N, 1°53'31.70"E
0 references
08903
0 references
LA AGREGACION AMILOIDE DE PROTEINAS SE ASOCIA A UN NUMERO CRECIENTE DE TRASTORNOS DEBILITANTES O INCLUSO FATALES. EXISTE UNA NECESIDAD URGENTE DE DIAGNOSTICO Y TRATAMIENTO DE ESTAS ENFERMEDADES, NO SOLO PARA PREVENIR EL SUFRIMIENTO DE LOS PACIENTES, SINO TAMBIEN PARA REDUCIR LA CARGA ECONOMICA Y EMOCIONAL QUE RECAE EN EL RESTO DE LA POBLACION. ESTE PROYECTO PRETENDE APROVECHAR NUESTRA EXPERIENCIA EN EL AREA PARA AVANZAR EN ESTA DIRECCION, CONCENTRANDONOS EN DOS ENFERMEDADES: LA AMILOIDOSIS POR TRANSTIRETINA (ATTR) Y EL PARKINSON. _x000D_ ATTR ES LA FORMA MAS COMUN DE AMILOIDOSIS FAMILIAR. EN LA ATTR, MUTACIONES DESESTABILIZANTES DE LA PROTEINA TRANSTIRETINA (TTR) DAN LUGAR A LA FORMACION DE FIBRAS AMILOIDES, QUE DEPENDIENDO DE LA MUTACION, SE DEPOSITAN EN DIFERENTES ORGANOS TALES COMO EL CEREBRO, LOS NERVIOS O EL MIOCARDIO, DANDO LUGAR A LAS DIVERSAS FORMAS DE LA ENFERMEDAD. PARA EVITAR SU PROGRESO ES NECESARIO UN TRASPLANTE DE HIGADO O DE CORAZON. SIN EMBARGO, EL USO DE CHAPERONAS FARMACOLOGICAS QUE ESTABILIZAN LA ESTRUCTURA DE TTR ESTA EMERGIENDO COMO UN METODO TERAPEUTICO NO INVASIVO PARA DETENER EL CURSO DE LA ENFERMEDAD. EN ESTE CONTEXTO, HEMOS REPOSICIONADO UNA MOLECULA ORIGINALMENTE DESTINADA PARA TRATAR PARKINSON, COMO, TAL VEZ, EL FARMACO MAS EFICAZ PARA TRATAR ATTR, YA EN ENSAYOS CLINICOS. EN ESTE PROYECTO BUSCAMOS TANTO PROBAR SU EFICACIA PARA LAS FORMAS DE LA ENFERMEDAD NO TRATADAS ANTERIORMENTE, CON ESPECIAL ENFASIS EN LAS CEREBRALES, COMO REDISEÑAR LA ESTRUCTURA DEL FARMACO PARA OBTENER UNA SEGUNDA GENERACION DE DROGAS AUN MAS POTENTE._x000D_ LA ENFERMEDAD DE PARKINSON (EP) ES EL SEGUNDO TRASTORNO NEURODEGENERATIVO MAS COMUN, Y ES TODAVIA INCURABLE. LA EP SE ASOCIA CON LA MUERTE DE LAS NEURONAS DOPAMINERGICAS EN EL CEREBRO. HAY PRUEBAS QUE INDICAN QUE LA AGREGACION DE LA PROTEINA A-SINUCLEINA (A-SYN) ES UN ACONTECIMIENTO CLAVE EN LA PATOGENESIS DE LA EP, SIENDO PUES UNA DIANA TERAPEUTICA PRIVILEGIADA. COMO RESULTADO DE UN INTENSO TRABAJO DE COLABORACION, HEMOS IDENTIFICADO RECIENTEMENTE 30 COMPUESTOS CAPACES DE INHIBIR LA AGREGACION DE A-SYN CON ALTA EFICACIA IN VITRO. AQUI, NOS PROPONEMOS PROFUNDIZAR EN LA CARACTERIZACION DE LAS PROPIEDADES TERAPEUTICAS DE ESTOS COMPUESTOS PARA EL POTENCIAL TRATAMIENTO DEL PARKINSON._x000D_ LA DETECCION TEMPRANA DE LA EP ES UN OBJETIVO LARGAMENTE PERSEGUIDO. UN TEST DE DIAGNOSTICO REVOLUCIONARIA LA ATENCION CLINICA, LA INVESTIGACION Y EL TRATAMIENTO DEL PARKINSON. ANALISIS BIOQUIMICOS EN SANGRE O LIQUIDO CEFALORRAQUIDEO (CSF) HAN DEMOSTRADO UN INCREMENTO DE AGREGADOS DE A-SYN EN LOS BIOFLUIDOS DE PACIENTES CON LA EP, LO QUE SUGIERE QUE PODRIAN CONSTITUIR UN BIOMARCADOR PARA EL DIAGNOSTICO DE LA ENFERMEDAD. AQUI NOS PROPONEMOS UTILIZAR UN ENFOQUE MULTIPLE PARA EL DESARROLLO DE UN ENSAYO DE DIAGNOSTICO SENSIBLE Y AUTOMATIZABLE, BASADO EN LA DETECCION TEMPRANA Y ESPECIFICA DE AGREGADOS DE A-SYN EN FLUIDOS BIOLOGICOS._x000D_ A PESAR DE SU ASOCIACION CON ENFERMEDADES, MUCHOS ORGANISMOS UTILIZAN LA ESTRUCTURA AMILOIDE PARA FINES FUNCIONALES. DE HECHO, SU EXTRAORDINARIA ESTABILIDAD Y MODULARIDAD LA CONVIERTE EN UNA DIANA ATRACTIVA EN NANOTECNOLOGIA. COMO OBJETIVO FINAL, PRETENDEMOS EXPLOTAR NUESTRO CAPACIDAD DE ANALISIS COMPUTACIONAL PARA GENERAR PEPTIDOS CORTOS CON CAPACIDAD DE AUTO-ENSAMBLARSE EN FIBRAS AMILOIDES Y ASI CONSTRUIR NUEVOS NANOMATERIALES QUE CONTENGAN PROPORCIONES CONTROLADAS DE DIFERENTES PROTEINAS ACTIVAS CON POTENCIALES APLICACIONES EN AREAS TAN DIVERSAS COMO LA QUIMICA, LA ELECTRONICA O LA MEDICINA (Spanish)
0 references
AMYLOID PROTEIN AGGREGATION IS ASSOCIATED WITH AN INCREASING NUMBER OF DEBILITATING OR EVEN FATAL DISORDERS. THERE IS AN URGENT NEED FOR DIAGNOSIS AND TREATMENT OF THESE DISEASES, NOT ONLY TO PREVENT THE SUFFERING OF PATIENTS, BUT ALSO TO REDUCE THE ECONOMIC AND EMOTIONAL BURDEN THAT FALLS ON THE REST OF THE POPULATION. THIS PROJECT AIMS TO TAKE ADVANTAGE OF OUR EXPERIENCE IN THE AREA TO MOVE FORWARD IN THIS DIRECTION, CONCENTRATING ON TWO DISEASES: TRANSTHYRETIN AMYLOIDOSIS (ATTR) AND PARKINSON’S. _x000D_ attr IS THE COMMUN FORM OF FAMILY AMMILIDOSIS. IN ATTR, DESTABILISING MUTATIONS OF THE TRANSTHYRETIN PROTEIN (TTR) RESULT IN THE FORMATION OF AMYLOID FIBERS, WHICH, DEPENDING ON THE MUTATION, ARE DEPOSITED IN DIFFERENT ORGANS SUCH AS THE BRAIN, NERVES OR MYOCARDIUM, RESULTING IN THE VARIOUS FORMS OF THE DISEASE. A LIVER OR HEART TRANSPLANT IS NEEDED TO PREVENT THEIR PROGRESS. HOWEVER, THE USE OF PHARMACOLOGICAL CHAPERONAS THAT STABILISE THE TTR STRUCTURE IS EMERGING AS A NON-INVASIVE THERAPEUTIC METHOD TO STOP THE COURSE OF THE DISEASE. IN THIS CONTEXT, WE HAVE REPOSITIONED A MOLECULA ORIGINALLY INTENDED TO TREAT PARKINSON, AS, PERHAPS, THE MOST EFFECTIVE DRUG TO TREAT ATTR, ALREADY IN CLINICAL TRIALS. In this project we are looking forward to your effectiveness for the forms of untreated disease, with special emphasis on CEREBRALS, as redesigned the structure of the drug in order to perform a second management of drugs even more importantly._x000D_ PARKINSON’S DISEASE (EP) IS THE SECOND TRANSTORN neurodegenerative second and it’s all incredulable. PE IS ASSOCIATED WITH THE DEATH OF DOPAMINERGIC NEURONS IN THE BRAIN. THERE IS EVIDENCE THAT THE AGGREGATION OF PROTEIN A-SINUCLEIN (A-SYN) IS A KEY EVENT IN THE PATHOGENESIS OF PE, THUS BEING A PRIVILEGED THERAPEUTIC DIANA. AS A RESULT OF INTENSE COLLABORATION, WE HAVE RECENTLY IDENTIFIED 30 COMPOUNDS CAPABLE OF INHIBITING A-SYN AGGREGATION WITH HIGH IN VITRO EFFICACY. Here, we PROFUNDATE IN THE CHARACTERISATION OF THE TERAPEUTIC OWNERS OF THIS COMPURES FOR PARKINSON’S POTENTIAL TREATMENT._x000D_ The TEMPREAN DETECTION OF THE EP IS A LARGAMENT PERSEGUE OBJECTIVE. A REVOLUTIONARY DIAGNOSTIC TEST THE CLINICAL CARE, RESEARCH AND TREATMENT OF PARKINSON’S. BIOCHEMICAL ANALYSIS IN BLOOD OR CEREBROSPINAL FLUID (CSF) HAS SHOWN AN INCREASE IN AGGREGATES OF A-SYN IN THE BIOFLUIDES OF PATIENTS WITH PE, SUGGESTING THAT THEY COULD CONSTITUTE A BIOMARKER FOR THE DIAGNOSIS OF THE DISEASE. Here we propose to use a multiplicity focus for the development of a sensibly and automable diagnostic filling, based on the early and specific development of a-syn influxes in biologic fuluids._x000D_ TO PEOPLE THIS ASSOCIATION WITH DISEASES, MUCHOS ORGANISMUS USE AMERICAL STRUCTURE FOR FUNCIONAL FINES. IN FACT, ITS EXTRAORDINARY STABILITY AND MODULARITY MAKES IT AN ATTRACTIVE DIANA IN NANOTECHNOLOGY. AS A FINAL OBJECTIVE, WE INTEND TO EXPLOIT OUR COMPUTATIONAL ANALYSIS CAPABILITY TO GENERATE SHORT PEPTIDES WITH THE ABILITY TO SELF-ASSEMBLE INTO AMYLOID FIBERS AND THUS BUILD NEW NANOMATERIALS THAT CONTAIN CONTROLLED PROPORTIONS OF DIFFERENT ACTIVE PROTEINS WITH POTENTIAL APPLICATIONS IN AREAS AS DIVERSE AS CHEMISTRY, ELECTRONICS OR MEDICINE. (English)
12 October 2021
0 references
Sant Julià de Cerdanyola
0 references
Identifiers
BIO2016-78310-R
0 references